Návratnost kapitálu společnosti SinoMab BioScience
Jaká je hodnota metriky Návratnost kapitálu společnosti SinoMab BioScience?
Hodnota metriky Návratnost kapitálu společnosti SinoMab BioScience Limited je 0.00%
Jaká je definice metriky Návratnost kapitálu?
Return on capital employed (ROCE) je finanční ukazatel, který měří rentabilitu společnosti a efektivitu společnosti ve využívání vlastního kapitálu.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
Návratnost kapitálu společností v sektoru Health Care sektor na HKSE ve srovnání se společností SinoMab BioScience
Čemu se věnuje společnost SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Firmy s metrikou návratnost kapitálu podobnou společnosti SinoMab BioScience
- Hodnota metriky Návratnost kapitálu společnosti Omega Alpha Spac je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti The Gap je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti Elemental Royalties Ltd je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti Auburn National Bancorp je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti Galaxy Digital je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti The Gap je -0.01%
- Hodnota metriky Návratnost kapitálu společnosti SinoMab BioScience je 0.00%
- Hodnota metriky Návratnost kapitálu společnosti Tejon Ranch Co je 0.01%
- Hodnota metriky Návratnost kapitálu společnosti Glen Burnie Bancorp je 0.02%
- Hodnota metriky Návratnost kapitálu společnosti MSP Steel & Power je 0.02%
- Hodnota metriky Návratnost kapitálu společnosti TTL Beteiligungs- und Grundbesitz-AG je 0.03%
- Hodnota metriky Návratnost kapitálu společnosti First Foundation Inc je 0.03%
- Hodnota metriky Návratnost kapitálu společnosti FirstMark Horizon Acquisition je 0.03%